<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13007">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00434876</url>
  </required_header>
  <id_info>
    <org_study_id>101206</org_study_id>
    <nct_id>NCT00434876</nct_id>
  </id_info>
  <brief_title>The Effects of Quetiapine (Seroquel XR) on Sleep During Alcohol Abstinence</brief_title>
  <official_title>The Effects of Quetiapine on Sleep During Alcohol Abstinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Subhajit Chakravorty</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philadelphia Veterans Affairs Medical Center</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine how efficacy of quetiapine (seroquel XR)
      in improving the sleep in recovering alcohol dependent subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sober alcohol dependent subjects frequently complain of difficulty falling asleep as well as
      staying asleep which may eventually lead to relapse. Novel antipsychotic medications such as
      quetiapine have shown some efficacy in treating alcoholism and have also shown some benefit
      in improving insomnia.

      The primary aim of this study is to determine the degree to which quetiapine improves sleep
      in veterans during the early phase of recovery from alcohol dependence. The sleep efficiency
      from an in-lab polysomnogram will be the primary outcome measure. Secondary measures of
      sleep will include the Pittsburgh Sleep Quality Index, Insomnia Severity Index, and
      actigraphy. Other additional aims will explore for alcohol use and cravings, change in
      psychiatric symptoms using the The Time Line Follow Back measure, Penn Alcohol Craving Scale
      (PACS), the Patient Health Questionnaire-9 item scale (PHQ-9), and the Beck's Anxiety
      Inventory (BAI) respectively.

      Twenty four subjects within the first year of sobriety will be enrolled. Participants will
      be undergo an extensive baseline screening procedure. After 2 consecutive in-laboratory
      polysomnograms they will be treated with either Quetiapine XR or matching placebo pills
      targetting a dose of 400 mg a night. The treatment duration will be 8 weeks and during the
      eight week of treatment they will undergo 2 more nights of in-laboratory polysomnogram. All
      subjects will also receive Medical Management therapy, a standardized psychosocial
      intervention which is medically-based and focusses on alcohol abstinence and medication
      compliance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Sleep Efficiency (From an In-laboratory Polysomnogram)</measure>
    <time_frame>Baseline, and week 8 of treatment.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The fraction of time spent asleep to the total time in bed (%).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insomnia Severity Index (ISI)</measure>
    <time_frame>Baseline, weeks 1, 3, 5, and 7 of treatment.</time_frame>
    <safety_issue>No</safety_issue>
    <description>ISI total score; this scale assesses for global insomnia severity (range 0-24). Higher scale scores indicate higher insomnia severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh Sleep Quality Index (PSQI)</measure>
    <time_frame>Baseline, weeks 4, and 9.</time_frame>
    <safety_issue>No</safety_issue>
    <description>PSQI total score (range 0-21). A PSQI total score &gt; 5 indicates insomnia, with higher scores denoting a decrease in sleep quality.
The PSQI global score assesses for the overall quality of sleep and is computed by adding the 7 component scale scores. This widely used 19-item self-rated scale evaluates the subjective quality of sleep over the last 4 weeks. The PSQI was administered at baseline, and weeks 4, and 9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wake After Sleep Onset Time (WASO) From an In-laboratory Polysomnogram.</measure>
    <time_frame>Baseline, and week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>The amount of time spent awake after initially falling asleep and before final awakening (in minutes). None to a fewer minutes is better (than a higher number of minutes).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Alcoholism</condition>
  <condition>Sleep Initiation and Maintenance Disorders</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quetiapine XR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine XR</intervention_name>
    <description>Quetiapine is a second generation antipsychotic medication, which has also recently shown to be associated with properties of mood stabilization in bipolar disorder.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Seroquel XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo.</intervention_name>
    <description>Inactive or inert pill which will be used as a comparator.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: subjects between the ages of 18-65 years, with a DSM-IV diagnosis of
        current alcohol dependence (past year), can speak, understand, and print in English, and
        is capable of giving written informed consent

        Exclusion Criteria: Positive urine drug screen for opioids, cocaine, or amphetamine
        (excluding THC), dependence on other drugs excluding alcohol/nicotine/cannabis over the
        past year, unstable psychiatric, medical disorders, cataracts [posterior capsular/ nuclear
        (grade NS3 or more), currently on any maintenance psychotropic medications affecting
        sleep, currently pregnant, nursing, or not using a reliable method of contraception;
        history of hypersensitivity to antipsychotic drugs, including quetiapine, severe cognitive
        impairment, severe untreated obstructive sleep apnea, and inadequately controlled diabetes
        mellitus.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Subhajit Chakravorty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Philadelphia, OPC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Philadelphia, OPC</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 9, 2013</lastchanged_date>
  <firstreceived_date>February 12, 2007</firstreceived_date>
  <firstreceived_results_date>May 16, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Philadelphia Veterans Affairs Medical Center</investigator_affiliation>
    <investigator_full_name>Subhajit Chakravorty</investigator_full_name>
    <investigator_title>Staff Physician</investigator_title>
  </responsible_party>
  <keyword>Alcoholism</keyword>
  <keyword>Insomnia</keyword>
  <keyword>Quetiapine</keyword>
  <keyword>Seroquel</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alcohol Abstinence</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Quetiapine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Addiction psychiatry clinic, behavioral health laboratory, and self referrals solicited through flyers.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Quetiapine XR</title>
          <description>The pills were taken at bedtime and the dose was titrated flexibly in the following fashion over the first week: 50 mg dose for 2 nights, followed by 200 mg a night for 2 nights, and then 300 mg a night for 2 nights and to a final dose of 400 mg daily starting on night # 7. Medication taper commenced at week 8 in the reverse stepwise fashion after the second set of two polysomnograms.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>The matching placebo pills were similarly taken at bedtime and the dose was titrated flexibly in the following fashion over the first week: 50 mg dose for 2 nights, followed by 200 mg a night for 2 nights, and then 300 mg a night for 2 nights and to a final dose of 400 mg daily starting on night # 7. Medication taper commenced at week 8 in the reverse stepwise fashion after the second set of two polysomnograms.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Quetiapine</title>
          <description>Quetiapine XR</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="20"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="53" spread="6"/>
                <measurement group_id="B2" value="51" spread="8"/>
                <measurement group_id="B3" value="52" spread="7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sleep Efficiency (From an In-laboratory Polysomnogram)</title>
        <description>The fraction of time spent asleep to the total time in bed (%).</description>
        <time_frame>Baseline, and week 8 of treatment.</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine XR</title>
            <description>Quetiapine XR</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Sleep Efficiency (From an In-laboratory Polysomnogram)</title>
            <description>The fraction of time spent asleep to the total time in bed (%).</description>
            <units>percentage</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Sleep Efficiency (baseline)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="70.70" spread="17.49"/>
                  <measurement group_id="O2" value="78.63" spread="12.89"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sleep Efficiency (after 8 weeks of treatment)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="79.45" spread="16.52"/>
                  <measurement group_id="O2" value="82.80" spread="11.57"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.49</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insomnia Severity Index (ISI)</title>
        <description>ISI total score; this scale assesses for global insomnia severity (range 0-24). Higher scale scores indicate higher insomnia severity.</description>
        <time_frame>Baseline, weeks 1, 3, 5, and 7 of treatment.</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine XR</title>
            <description>Quetiapine XR</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Insomnia Severity Index (ISI)</title>
            <description>ISI total score; this scale assesses for global insomnia severity (range 0-24). Higher scale scores indicate higher insomnia severity.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>ISI (baseline)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17.00" spread="4.08"/>
                  <measurement group_id="O2" value="14.80" spread="7.14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ISI (week 7)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.40" spread="4.83"/>
                  <measurement group_id="O2" value="6.70" spread="7.34"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.04</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pittsburgh Sleep Quality Index (PSQI)</title>
        <description>PSQI total score (range 0-21). A PSQI total score &gt; 5 indicates insomnia, with higher scores denoting a decrease in sleep quality.
The PSQI global score assesses for the overall quality of sleep and is computed by adding the 7 component scale scores. This widely used 19-item self-rated scale evaluates the subjective quality of sleep over the last 4 weeks. The PSQI was administered at baseline, and weeks 4, and 9.</description>
        <time_frame>Baseline, weeks 4, and 9.</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine XR</title>
            <description>Quetiapine XR</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Pittsburgh Sleep Quality Index (PSQI)</title>
            <description>PSQI total score (range 0-21). A PSQI total score &gt; 5 indicates insomnia, with higher scores denoting a decrease in sleep quality.
The PSQI global score assesses for the overall quality of sleep and is computed by adding the 7 component scale scores. This widely used 19-item self-rated scale evaluates the subjective quality of sleep over the last 4 weeks. The PSQI was administered at baseline, and weeks 4, and 9.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>PSQI (baseline)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14.70" spread="1.94"/>
                  <measurement group_id="O2" value="14.60" spread="1.71"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PSQI (week 4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.20" spread="2.61"/>
                  <measurement group_id="O2" value="13.80" spread="2.04"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PSQI (week 9)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14.50" spread="2.56"/>
                  <measurement group_id="O2" value="13.80" spread="2.78"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.57</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Wake After Sleep Onset Time (WASO) From an In-laboratory Polysomnogram.</title>
        <description>The amount of time spent awake after initially falling asleep and before final awakening (in minutes). None to a fewer minutes is better (than a higher number of minutes).</description>
        <time_frame>Baseline, and week 8</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine XR</title>
            <description>Quetiapine XR</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Wake After Sleep Onset Time (WASO) From an In-laboratory Polysomnogram.</title>
            <description>The amount of time spent awake after initially falling asleep and before final awakening (in minutes). None to a fewer minutes is better (than a higher number of minutes).</description>
            <units>minutes</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>WASO (baseline)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="101.87" spread="81.80"/>
                  <measurement group_id="O2" value="61.17" spread="37.77"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WASO (week 8)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="60.71" spread="71.41"/>
                  <measurement group_id="O2" value="66.99" spread="60.62"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.03</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Quetiapine</title>
          <description>Quetiapine XR</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Relapse to heavy alcohol use leading to inpatient admission</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Somatic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Increased apetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Decreased motivation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The limitations of this study include the small sample size, and assessment of PSQI, PHQ-9, BAI, and SF-12 at week 9 (immediately after washout from the study drug). The corruption of stored online actigraphic sleep data prevented its interpretation.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Subhajit Chakravorty</name_or_title>
      <organization>Philadelphia VAMC</organization>
      <phone>215-823-5800 ext 3405</phone>
      <email>Subhajit.Chakravorty@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
